Author(s):
Mohammad Intakhab Alam, Syam Mohan, Mohammad Ashafaq, Yosif Almoshari, Hafiz A. Makeen, Sohail Hussain
Email(s):
mialam@jazanu.edu.sa , smohan@jazanu.edu.sa , mashfaqisha@jazanu.edu.sa , yalmoshari@jazanu.edu.sa , hafiz@jazanu.edu.sa , shussainamu@gmail.com
DOI:
10.52711/0974-360X.2024.00764
Address:
Mohammad Intakhab Alam1, Syam Mohan2,3, Mohammad Ashafaq4, Yosif Almoshari1, Hafiz A. Makeen5, Sohail Hussain4*
1Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
2Substance Abuse and Toxicology Research Centre, Jazan University, Jazan, Saudi Arabia.
3School of Health Sciences, University of Petroleum and Energy Studies, Dehradun, Uttarakhand, India.
4Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
5Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
*Corresponding Author,
Published In:
Volume - 17,
Issue - 10,
Year - 2024
Cite this article:
Mohammad Intakhab Alam, Syam Mohan, Mohammad Ashafaq, Yosif Almoshari, Hafiz A. Makeen, Sohail Hussain. Determining the anticancer effect of Gefitinib-loaded NLCs through investigating the inflammatory cytokine (JAK-STAT) pathway. Research Journal of Pharmacy and Technology. 2024; 17(10):4968-4. doi: 10.52711/0974-360X.2024.00764